Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Radiol. Jun 28, 2013; 5(6): 248-252
Published online Jun 28, 2013. doi: 10.4329/wjr.v5.i6.248
Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study
Nadia Wiazzane, Cyrus Chargari, Corine Plancher, Jerome Tamburini, Bernard Asselain, Alain Fourquet, Didier Bouscary, Youlia M Kirova
Nadia Wiazzane, Cyrus Chargari, Alain Fourquet, Youlia M Kirova, Department of Radiation Oncology, Institut Curie, 75005 Paris, France
Corine Plancher, Bernard Asselain, Department of Biostatistics, Institut Curie, 75005 Paris, France
Jerome Tamburini, Didier Bouscary, Department of Haematology, Cochin Hospital, 75014 Paris, France
Author contributions: Wiazzane N contributed to the patient’s data management and paper redaction; Chargari C contributed to the paper redaction; Plancher C contributed to the patient’s data management, statistical analysis; Tamburini J contributed to the patients’ management and paper redaction; Asselain B contributed to the data management, statistical analysis; Fourquet A contributed to the patient’s data management and paper redaction; Bouscary D contributed to the patients’ treatment, patient’s data management and paper redaction; Kirova YM contributed to the original idea, patients’ treatment, patient’s data management and paper redaction; Wiazzane N and Chargari C equally contributed to this work.
Correspondence to: Youlia M Kirova, MD, Department of Radiation Oncology, Institut Curie, 26, rue d’Ulm, 75005 Paris, France. youlia.kirova@curie.net
Telephone: +33-144-324193 Fax: +33-144-324616
Received: February 21, 2013
Revised: April 4, 2013
Accepted: June 1, 2013
Published online: June 28, 2013
Core Tip

Core tip: Solitary plasmacytomas consist of a localized collection of malignant plasma cells without evidence of a systemic plasma cell proliferative disorder. It accounts for about 5% of all plasma cell neoplasms and may present with a single bone lesion (single bone plasmacytoma) or as a single extramedullary or extra-osseous lesion. Using helical tomotherapy®, we could deliver a highly conformal irradiation concurrently with a molecularly targeted therapy. This association yielded in a high response rate and a low toxicity. A prospective study with longer follow-up will help determining the true benefit of such strategy.